{"nctId":"NCT02545075","briefTitle":"A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine","startDateStruct":{"date":"2015-10-31","type":"ACTUAL"},"conditions":["Melanoma"],"count":182,"armGroups":[{"label":"Ipilimumab","type":"EXPERIMENTAL","interventionNames":["Drug: Ipilimumab"]},{"label":"Dacarbazine","type":"EXPERIMENTAL","interventionNames":["Drug: Dacarbazine"]}],"interventions":[{"name":"Ipilimumab","otherNames":["MDX-010"]},{"name":"Dacarbazine","otherNames":["DTIC"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Chinese males and females ≥ 18 years of age\n* Histologic diagnosis of malignant melanoma\n* Chemotherapy naive Stage IV melanoma (AJCC 2010)\n* Life expectancy of ≥ 16 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Evidence of brain metastases on brain imaging\n* Primary ocular or mucosal melanoma\n* Any other malignancy from which the patient has been disease-free for less than 5 years\n* BRAF status cannot be determined by Screening test\n* Human Immunodeficiency Virus (HIV) positive or hepatitis B surface antigen (HBsAg) positive, or active Hepatitis C infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Two-Years Survival Rate","description":"Two-year survival rate is defined as the probability that a subject is alive at 2 years following the randomization date and will be estimated via the Kaplan-Meier (KM) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.98","spread":null},{"groupId":"OG001","value":"34.09","spread":null}]}]}]},{"type":"SECONDARY","title":"One-Year Survival Rate","description":"Survival rate at 1 year is defined as the probability that a subject is alive at 1 year following the randomization date and will be estimated via the Kaplan-Meier (KM) method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.68","spread":null},{"groupId":"OG001","value":"64.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined for each subject as the time between randomization date and the date of death (of any cause).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.08","spread":null},{"groupId":"OG001","value":"14.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival ( PFS)","description":"PFS is defined for each subject as the time between randomization date and the date of progression or death, whichever occurs first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":null},{"groupId":"OG001","value":"1.84","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate ( DCR )","description":"Primary DCR is defined as the number of subjects in the arm with Best Overall Response (BOR) of complete response (CR), partial response (PR), or stable disease (SD), divided by the total number of randomized subjects in the arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"31.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Response Rate ( BORR )","description":"BORR definition is defined as the number of subjects in the arm with a BOR of CR or PR, divided by the total number of randomized subjects in the arm.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response ( DoR)","description":"DoR definition for the response evaluable subjects whose BOR is CR or PR is defined as the time between the date of response of CR or PR (whichever occurs first) and the first date of progressive disease (PD) or the date of death (whichever occurs first).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","spread":null},{"groupId":"OG001","value":"7.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Stable Disease ( DoSD )","description":"Primary duration of stable disease (DoSD) definition for the randomized subjects whose BOR is SD is defined as the time between the randomization date and the first date of PD or the date of death (whichever occurs first).\"","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"9.40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":122},"commonTop":["Alanine aminotransferase increased","Decreased appetite","Nausea","Aspartate aminotransferase increased","Rash"]}}}